Study summary

Ten years on, double immunotherapy has kept more than a third of people with advanced melanoma alive

CheckMate 067 10-year results · 945 people, phase 3 · Published September 2024, New England Journal of Medicine

What was tested

Nivolumab plus ipilimumab, nivolumab alone, or ipilimumab alone, as first treatment for advanced melanoma, followed for 10 years.

What they found

• Median survival was 71.9 months with the combination, 36.9 with nivolumab and 19.9 with ipilimumab.
• 37% of people on the combination were still alive at the end of the trial.
• People alive and progression-free at 3 years had a 96% chance of being alive from melanoma at 10 years.

What it means

Advanced melanoma, once fatal within a year, now has long-term survivors; the challenge is helping the rest.